Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Zeta Global Holdings Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $289.9 (market cap $39.89B), while Zeta Global Holdings Corp trades at $21.86 (market cap $5.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.4× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ZETA | |
|---|---|---|
Market Cap | $39.89B | $5.36B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.24 |
52-Week Low | $278.09 | $14.00 |
Enterprise Value | $38.15B | $5.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ZETA trades at $21.49, down 1.94% on the day, with a bullish technical signal from moving averages and strong analyst support. The company demonstrates robust revenue growth, reaching $1.30B in 2025, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its strategic AI partnership with Palantir and expansion of its Athena AI platform, driving positive investor sentiment despite current negative profitability metrics.
The outlook for ZETA is positive, with a consensus price target of $27.50 implying 28% upside. Key opportunities include AI-driven growth and market share gains, but risks involve persistent negative net margins and cash flow challenges. Investors should weigh the strong growth trajectory against profitability concerns before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
